Food and Drug Administration-Regulated Products Containing Nanotechnology Materials; Public Meeting, 46232-46233 [06-6867]
Download as PDF
<![CDATA[
46232
Federal Register / Vol. 71, No. 155 / Friday, August 11, 2006 / Notices
Dated: August 4, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–13114 Filed 8–10–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N–0107]
Food and Drug AdministrationRegulated Products Containing
Nanotechnology Materials; Public
Meeting
AGENCY:
Food and Drug Administration,
HHS.
Notice of public meeting;
request for comments.
hsrobinson on PROD1PC67 with NOTICES1
ACTION:
SUMMARY: The Food and Drug
Administration (FDA) will hold a public
meeting October 10, 2006, on FDAregulated products containing
nanotechnology materials, and has
opened a docket on FDA-regulated
products containing nanotechnology
materials. The purpose of the meeting
will be to help FDA further its
understanding of developments in
nanotechnology materials that pertain to
FDA-regulated products. FDA is
interested in learning about the kinds of
new nanotechnology material products
under development in the areas of foods
(including dietary supplements), food
and color additives, animal feeds,
cosmetics, drugs and biologics, and
medical devices, whether there are new
or emerging scientific issues that should
be brought to FDA’s attention, and any
other scientific issues about which the
regulated industry, academia, and the
interested public may wish to inform
FDA concerning the use of
nanotechnology materials in FDAregulated products.
DATES AND TIMES: The public meeting
will be held October 10, 2006, from 9
a.m. to 5 p.m.
REGISTRATION: You may register at
https://www.fda.gov/nanotechnology/.
We will also post the agenda at https://
www.fda.gov/nanotechnology/ prior to
the meeting.
ADDRESSES: The public workshop will
be held at the Natcher Auditorium,
National Institutes of Health Campus,
9000 Rockville Pike, bldg. 45, Bethesda,
MD. We will also post the address for
the meeting at https://www.fda.gov/
nanotechnology/.
Written or electronic comments may
be submitted by November 10, 2006.
Submit written comments to the
VerDate Aug<31>2005
15:03 Aug 10, 2006
Jkt 208001
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. Submit electronic comments
to https://www.fda.gov/dockets/
ecomments. All comments should be
identified with the docket number
found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Poppy Kendall, Food and Drug
Administration (HF–11), 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
3360, FAX: 301–594–6777, e-mail:
poppy.kendall@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Why Are We Holding a Public
Meeting?
Nanotechnology is defined in a
variety of ways. The National
Nanotechnology Initiative (a U.S.
Government research and development
coordinating program) refers to
nanotechnology as ‘‘the understanding
and control of matter at dimensions of
roughly 1 to 100 nanometers, where
unique phenomena enable novel
applications’’ (https://www.nano.gov). A
nanometer is a billionth of a meter, and
is approximately the width of 10
hydrogen atoms lined up side by side.
(A human hair is about 80,000
nanometers in width. Deoxyribonucleic
acid (DNA) is about 2.5 nanometers in
width.)
Due to their small size and extremely
high ratio of surface area to volume,
nanotechnology materials often have
chemical or physical properties that are
different from those of their larger
counterparts. Such differences include
altered magnetic properties, altered
electrical or optical activity, increased
structural integrity, and increased
chemical and biological activity.
Because of these properties,
nanotechnology materials have great
potential for use in a vast array of
products. Also because of some of their
special properties, they may pose
different safety issues than their larger
counterparts. Of particular interest to
FDA, nanotechnology materials may
enable new developments in implants
and prosthetics, drug delivery, and food
processing, and may already be in use
in some cosmetics and sunscreens. As
part of its critical path initiative, FDA is
interested in learning if there are
opportunities for it to help overcome
scientific hurdles that may be inhibiting
the use of nanotechnology in medical
product development.
We will be holding this meeting
because we are interested in learning
about the kinds of new nanotechnology
material products under development in
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
the areas of foods (including dietary
supplements), food and color additives,
animal feeds, cosmetics, drugs and
biologics, and medical devices, whether
there are new or emerging scientific
issues that should be brought to FDA’s
attention, including issues related to the
safety of nanotechnology materials, and
any other issues about which the
regulated industry, academia, and the
interested public may wish to inform
FDA concerning the use of
nanotechnology materials in FDAregulated products.
The public meeting will be chaired by
the FDA Nanotechnology Task Force.
Acting FDA Commissioner Andrew von
Eschenbach created this internal task
force to help the agency evaluate the
increasing use of nanotechnology
materials in FDA-regulated products.
For more information about FDA’s
role regarding nanotechnology products,
see our Web page at https://www.fda.gov/
nanotechnology/.
II. How Can You Participate?
You can participate through oral
presentation at the meeting or through
written or electronic material submitted
to the docket. In response to the first
notice of this meeting (71 FR 19523,
April 14, 2006) we received a large
number of responses indicating interest
in attending and presenting, and the
responses indicated interest in a variety
of topics. Therefore, in order to provide
the most value to those attending who
may be interested in a particular topic,
we are likely to divide the meeting into
topic areas (for separate, concurrent
sessions on those topics) and one
general session. Participants would be
asked to express a preference for either
one of the concurrent sessions or the
general session in which to make a
presentation. Time allotted for each
presentation will depend on the
presentation requests received for that
session. Furthermore, given the number
of responses received, it is likely that it
will be necessary to limit presentations
to one per individual/organization.
In addition to a session that has a
more general focus, we are considering
the following three breakout sessions:
(1) Topically-administered drugs,
biologics, devices and cosmetics; (2)
other drugs, biologics and devices; (3)
foods (including dietary supplements)
and food and color additives, and
animal Feeds.
We ask that you register early (see
REGISTRATION) if you intend to provide
an oral presentation. The information
provided during registration will help
us determine further how to organize
the day. The final agenda will depend
E:\FR\FM\11AUN1.SGM
11AUN1
Federal Register / Vol. 71, No. 155 / Friday, August 11, 2006 / Notices
on the nature of the requests made for
presentations.
III. Will Meeting Transcripts Be
Available?
Following the meeting, transcripts
will be available for review at the
Division of Dockets Management (see
ADDRESSES).
IV. How Should You Send Comments
on the Issues?
Interested persons may submit written
or electronic comments to the Division
of Dockets Management (see
ADDRESSES). Submit a single copy of
electronic comments or two paper
copies of any mailed comments, except
that individuals may submit one paper
copy. Comments are to be identified
with the docket number found in
brackets in the heading of this
document. Received comments may be
seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Dated: August 1, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 06–6867 Filed 8–8–06; 3:14 pm]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N–0292]
Unique Device Identification; Request
for Comments
AGENCY:
Food and Drug Administration,
HHS.
hsrobinson on PROD1PC67 with NOTICES1
ACTION:
Notice; request for comments.
SUMMARY: The Food and Drug
Administration (FDA) is issuing this
notice to request comments to help the
agency understand how the use of a
unique device identification (UDI)
system may improve patient safety, e.g.,
by reducing medical errors, facilitating
device recalls, and improving medical
device adverse event reporting. We are
also interested in understanding the
issues associated with the use of various
automatic identification technologies
(e.g., bar code, radiofrequency
identification). We invite comments
about specific UDI issues for medical
devices.
Submit written or electronic
comments by November 9, 2006.
ADDRESSES: Submit written comments
concerning this document to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
DATES:
VerDate Aug<31>2005
15:03 Aug 10, 2006
Jkt 208001
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. Submit electronic comments
to https://www.fda.gov/dockets/
ecomments.
FOR FURTHER INFORMATION CONTACT:
David Racine or Jay Crowley, Center for
Devices and Radiological Health (HFZ–
500), Food and Drug Administration,
1350 Piccard Dr., Rockville, MD 20850,
240–276–3400, e-mail:
CDRHUDI@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
On February 26, 2004, we published
a final rule (the ‘‘bar code rule’’) (69 FR
9120 ) requiring bar codes on certain
human drug and biological products to
help reduce medication errors in
hospitals and other health care settings.
The bar code is intended to enable
health care professionals to use bar code
scanning equipment in conjunction
with computerized medication
administration systems to verify that the
right drug, in the right dose, is being
given to the right patient at the right
time. This rule (now codified at 21 CFR
201.25 and 610.67) requires that
manufacturers encode the unique
National Drug Code (NDC) number in a
linear bar code on the product’s label.
The bar code rule, however, does not
apply to medical devices. In the bar
code rule, we stated that, unlike drugs,
medical devices do not have a
standardized, unique identifying system
comparable to the NDC number, and
that the absence of such a system
complicates efforts to put bar codes on
medical devices for purposes of
preventing medical errors (69 FR 9120
at 9132).
Since the issuance of the final bar
code rule, various entities, including
members of Congress and a consortium
of hospital groups, have asked that we
revisit the issue of bar coding medical
devices to improve patient safety;
improve quality of care; and encourage
cost effectiveness, e.g., of health care by
improving delivery and supply chain
efficiency (Refs. 1 and 2).
A. Stakeholder Meetings
In response to the interest in
revisiting the issue of bar coding
medical devices, FDA met with various
stakeholders, including device
manufacturers and distributors, hospital
associations, and other Federal agencies
such as the Agency for Healthcare
Research and Quality, Department of
Defense, Department of Veterans Affairs,
and Centers for Medicare and Medicaid
Services to solicit information and
comments about employing a uniform
system for the unique identification of
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
46233
medical devices. (References 3 and 5
contain summaries of some of these
meetings). We were interested in
hearing views about the value of a
uniform system of unique identifiers for
medical devices, what efforts or
initiatives are currently ongoing among
stakeholders, and the use of various
automatic identification technologies.
We were also interested in FDA’s role
related to the establishment and use of
a UDI system and whether FDA should
consider a voluntary or a mandatory
approach for such a system.
As a result of these meetings, FDA
learned that the majority of stakeholders
support the development of a uniform
system of unique identifiers as a way to
improve patient safety and recognized
other ancillary benefits such as better
management of the purchase,
distribution, and use of medical devices.
However, there were a variety of
opinions and experiences about how
best to implement such a system.
B. Report on Automatic and Unique
Identification of Medical Devices
In addition to holding stakeholder
meetings, we commissioned two reports
from outside experts to provide: A
general overview of some of the most
prevalent technologies available to
support automatic identification of
medical devices, the current published
positions and standards of various
stakeholders, and highlights of some of
the general applications reported in the
literature involving the use of such
systems for medical devices. (See Refs.
4 and 6 and https://www.fda.gov/cdrh/
ocd/udi/). The reports identified several
potential benefits to widespread use of
UDI, such as reducing medical errors,
facilitating recalls, improving medical
device reporting, and identifying
incompatibility with devices or
potential allergic reactions. The reports
further indicated that many issues have
to be addressed prior to successful
implementation of UDI for devices,
including determining the technology
needed to utilize UDI effectively,
identifying the data needed for patient
safety; development, maintenance, and
validation of a central data repository;
and harmonizing UDIs for the
international marketplace.
II. UDI Development and
Implementation
We are interested in receiving
comment on the possible role that a
unique device identification system
could have on improving patient safety,
for example, by reducing medical errors,
facilitating device recalls, and
improving medical device adverse event
reporting. In addition, we are interested
E:\FR\FM\11AUN1.SGM
11AUN1
]]>Agencies
[Federal Register Volume 71, Number 155 (Friday, August 11, 2006)]
[Notices]
[Pages 46232-46233]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-6867]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N-0107]
Food and Drug Administration-Regulated Products Containing
Nanotechnology Materials; Public Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) will hold a public
meeting October 10, 2006, on FDA-regulated products containing
nanotechnology materials, and has opened a docket on FDA-regulated
products containing nanotechnology materials. The purpose of the
meeting will be to help FDA further its understanding of developments
in nanotechnology materials that pertain to FDA-regulated products. FDA
is interested in learning about the kinds of new nanotechnology
material products under development in the areas of foods (including
dietary supplements), food and color additives, animal feeds,
cosmetics, drugs and biologics, and medical devices, whether there are
new or emerging scientific issues that should be brought to FDA's
attention, and any other scientific issues about which the regulated
industry, academia, and the interested public may wish to inform FDA
concerning the use of nanotechnology materials in FDA-regulated
products.
DATES AND TIMES: The public meeting will be held October 10, 2006, from
9 a.m. to 5 p.m.
REGISTRATION: You may register at https://www.fda.gov/nanotechnology/.
We will also post the agenda at https://www.fda.gov/nanotechnology/ prior to the meeting.
ADDRESSES: The public workshop will be held at the Natcher Auditorium,
National Institutes of Health Campus, 9000 Rockville Pike, bldg. 45,
Bethesda, MD. We will also post the address for the meeting at https://
www.fda.gov/nanotechnology/.
Written or electronic comments may be submitted by November 10,
2006. Submit written comments to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. Submit electronic comments to https://www.fda.gov/
dockets/ecomments. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Poppy Kendall, Food and Drug
Administration (HF-11), 5600 Fishers Lane, Rockville, MD 20857, 301-
827-3360, FAX: 301-594-6777, e-mail: poppy.kendall@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Why Are We Holding a Public Meeting?
Nanotechnology is defined in a variety of ways. The National
Nanotechnology Initiative (a U.S. Government research and development
coordinating program) refers to nanotechnology as ``the understanding
and control of matter at dimensions of roughly 1 to 100 nanometers,
where unique phenomena enable novel applications'' (https://
www.nano.gov). A nanometer is a billionth of a meter, and is
approximately the width of 10 hydrogen atoms lined up side by side. (A
human hair is about 80,000 nanometers in width. Deoxyribonucleic acid
(DNA) is about 2.5 nanometers in width.)
Due to their small size and extremely high ratio of surface area to
volume, nanotechnology materials often have chemical or physical
properties that are different from those of their larger counterparts.
Such differences include altered magnetic properties, altered
electrical or optical activity, increased structural integrity, and
increased chemical and biological activity. Because of these
properties, nanotechnology materials have great potential for use in a
vast array of products. Also because of some of their special
properties, they may pose different safety issues than their larger
counterparts. Of particular interest to FDA, nanotechnology materials
may enable new developments in implants and prosthetics, drug delivery,
and food processing, and may already be in use in some cosmetics and
sunscreens. As part of its critical path initiative, FDA is interested
in learning if there are opportunities for it to help overcome
scientific hurdles that may be inhibiting the use of nanotechnology in
medical product development.
We will be holding this meeting because we are interested in
learning about the kinds of new nanotechnology material products under
development in the areas of foods (including dietary supplements), food
and color additives, animal feeds, cosmetics, drugs and biologics, and
medical devices, whether there are new or emerging scientific issues
that should be brought to FDA's attention, including issues related to
the safety of nanotechnology materials, and any other issues about
which the regulated industry, academia, and the interested public may
wish to inform FDA concerning the use of nanotechnology materials in
FDA-regulated products.
The public meeting will be chaired by the FDA Nanotechnology Task
Force. Acting FDA Commissioner Andrew von Eschenbach created this
internal task force to help the agency evaluate the increasing use of
nanotechnology materials in FDA-regulated products.
For more information about FDA's role regarding nanotechnology
products, see our Web page at https://www.fda.gov/nanotechnology/.
II. How Can You Participate?
You can participate through oral presentation at the meeting or
through written or electronic material submitted to the docket. In
response to the first notice of this meeting (71 FR 19523, April 14,
2006) we received a large number of responses indicating interest in
attending and presenting, and the responses indicated interest in a
variety of topics. Therefore, in order to provide the most value to
those attending who may be interested in a particular topic, we are
likely to divide the meeting into topic areas (for separate, concurrent
sessions on those topics) and one general session. Participants would
be asked to express a preference for either one of the concurrent
sessions or the general session in which to make a presentation. Time
allotted for each presentation will depend on the presentation requests
received for that session. Furthermore, given the number of responses
received, it is likely that it will be necessary to limit presentations
to one per individual/organization.
In addition to a session that has a more general focus, we are
considering the following three breakout sessions: (1) Topically-
administered drugs, biologics, devices and cosmetics; (2) other drugs,
biologics and devices; (3) foods (including dietary supplements) and
food and color additives, and animal Feeds.
We ask that you register early (see REGISTRATION) if you intend to
provide an oral presentation. The information provided during
registration will help us determine further how to organize the day.
The final agenda will depend
[[Page 46233]]
on the nature of the requests made for presentations.
III. Will Meeting Transcripts Be Available?
Following the meeting, transcripts will be available for review at
the Division of Dockets Management (see ADDRESSES).
IV. How Should You Send Comments on the Issues?
Interested persons may submit written or electronic comments to the
Division of Dockets Management (see ADDRESSES). Submit a single copy of
electronic comments or two paper copies of any mailed comments, except
that individuals may submit one paper copy. Comments are to be
identified with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: August 1, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 06-6867 Filed 8-8-06; 3:14 pm]
BILLING CODE 4160-01-S
